Navigation Links
Annual Economic Impact of Chronic Disease on Ohio Economy is $56.8 Billion
Date:3/20/2008

Impact not inevitable with improved treatment and prevention of chronic

disease

CLEVELAND, March 20 /PRNewswire-USNewswire/ -- In a groundbreaking study released by the Milken Institute, the annual economic impact on Ohio's economy of the most common chronic diseases is calculated to be $56.8 billion. In the U.S. as a whole, the cost is a staggering $1 trillion, which could balloon to nearly $6 trillion by the middle of the century. Yet the news is not entirely grim because much of this cost is avoidable.

"An Unhealthy America: The Economic Burden of Chronic Disease" brings to light for the first time what is often overlooked in the discussion of the impact of chronic disease -- the economic loss associated with preventable illness and the cost to the nation's Gross Domestic Product (GDP) and American businesses in lost growth.

The results of the study were released at a joint forum hosted today by the Cleveland Clinic, University Hospitals, Rainbow Babies & Children's Hospital, the City of Cleveland Health Department and Cuyahoga County Board of Health, and the Ohio chapter of the Partnership to Fight Chronic Disease.

"The human toll of chronic disease in Ohio and the United States as a whole is obvious," said Matt Carroll, Health Director for the City of Cleveland. "The data presented by the Milken Institute today highlights the true cost burden of our failure to address chronic disease. We must reduce the rate of chronic disease to avoid potentially devastating economic damage to our state and nation."

According to the study, seven chronic diseases -- cancer, diabetes, hypertension, stroke, heart disease, pulmonary conditions and mental illness -- have a total impact on Ohio's economy of nearly $56.8 billion annually. Of this amount, $43.4 billion represents the cost of lost productivity. The national numbers are $1.3 trillion and $1.1 trillion, respectively.

"By investing in good health, we can add billions of dollars in economic growth in the coming decades," said Ross DeVol, Director of Health Economics and Regional Economics at the Milken Institute and principal author of the report. The good news is that with moderate improvements in prevention and early intervention such as reducing the rate of obesity, the savings to the economy would be enormous."

The study is the first of its kind to estimate the avoidable costs if a serious effort were made to improve Americans' health. Assuming modest improvements in preventing and treating disease, Milken Institute researchers determined that by 2023 the nation could avoid 40 million cases of chronic disease and reduce the economic impact of chronic disease by 27 percent, or $1.1 trillion annually. They report that the most important factor is obesity, which if rates declined could lead to $60 billion less in treatment costs and $254 billion in increased productivity.

Looking even further ahead, the report measures the possible cost to future generations if escalating disease leads to lower investments in education and training. In a snowball effect, the report warns, this loss of human capital and skill building could reduce the nation's economic output by as much as $5.7 trillion in real GDP by the year 2050.

In addition to providing national numbers, the report estimates current and future costs for each of the 50 states. According to the study, by making reasonable improvements in preventing and managing chronic disease, Ohio can avoid 1.5 million cases of chronic conditions in 2023 and reduce future economic costs of disease in Ohio sharply, by 27% ($40 billion). $32 billion of this would come from gains in productivity, and almost $9 billion would come from reduced treatment spending.

To reduce the human and economic cost of disease, the Milken Institute calls for:

-- More incentives to promote prevention and early intervention, and;

-- A renewed national commitment to achieve a "healthy body weight."

The report was created by researchers from the Milken Institute and was supported with a grant from the Pharmaceutical Research and Manufacturers of America (PhRMA), both of whom are partners in the PFCD.

"This study is a call to action. It's time for Americans to call for a change in how we effectively fight chronic disease. Chronic disease is a crucial driver of health care costs, and its rates are rising. We need to reverse this trend and we need to do it now. It's common sense," says PhRMA president and CEO Billy Tauzin.

The full report is available at http://www.milkeninstitute.org and http://www.fightchronicdisease.org. An interactive Web site with complete national- and state-level data for each of the chronic diseases is available at http://www.chronicdiseaseimpact.com.

About the Milken Institute: The Milken Institute is a nonprofit, independent economic think tank whose mission is to improve the lives and economic conditions of diverse populations around the world by helping business and public policy leaders identify and implement innovative ideas for creating broad-based prosperity. It is based in Santa Monica, CA. (http://www.milkeninstitute.org)

About The Partnership to Fight Chronic Disease: The Partnership to Fight Chronic Disease is a national coalition of patients, providers, community organizations, business and labor groups, and health policy experts committed to raising awareness of the number one cause of death, disability, and rising health care costs in the U.S.: chronic disease.


'/>"/>
SOURCE The Partnership to Fight Chronic Disease; The MilkenInstitute
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. NARSADs 5th Annual Mission Possible Symposium Offers Insight to PTSD and Other Mental Illnesses
2. Mirion Technologies to Showcase New Product Offerings for the Nuclear Industry During 10th Annual China International Nuclear Industry Exhibition
3. Abaxis, Inc. to Present at the Sidoti & Company Twelfth Annual New York Emerging Growth Institutional Investor Forum
4. ULURU Inc. to Present at Cowen and Company 28th Annual Health Care Conference 2008
5. Transdel Pharmaceuticals to Present at Cowen and Companys 28th Annual Health Care Conference
6. Flagship Global Health Announces Annual Meeting
7. Transition Therapeutics to Present at Cowen & Company 28th Annual Healthcare Conference
8. Covance to Present at Lehman Brothers 11th Annual Global Healthcare Conference
9. West Pharmaceutical Services to Present at the Lehman Brothers Eleventh Annual Global Healthcare Conference
10. Exelixis Announces March 19 Webcast of Presentation at the Lehman Brothers Annual Global Healthcare Conference
11. Edwards Lifesciences to Present at the Citi 5th Annual Small and Mid-Cap Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to Best Buy ... in the United States and Canada wear eyeglasses. Once considered to be a purely ... make a fashion statement. Even celebrities use glasses as a way of creating an ...
(Date:6/26/2016)... ... ... Kasmer, a legally blind and certified personal trainer is helping to develop a weight loss ... plans to fix the two major problems leading the fitness industry today:, ... , They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... California (PRWEB) , ... June 25, 2016 , ... "With ... fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... customizable and all within Final Cut Pro X . Simply select a ProHand ...
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... June 24, 2016 , ... The ... in Dallas that it will receive two significant new grants to support its ... PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists for ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ., ... developing innovative inhaled drugs, announced today that it was ... Investments reconstituted its comprehensive set of U.S. and ... "This is an important milestone for Pulmatrix," said Chief ... shareholder awareness of our progress in developing drugs for ...
(Date:6/23/2016)... -- MedSource announced today that it has selected Datatrial,s ... choice.  This latest decision demonstrates MedSource,s commitment to ... by offering a state-of-the-art electronic data capture (EDC) ... the EDC platform of choice in exchange for ... long been a preferred EDC platform by our ...
(Date:6/23/2016)... -- Research and Markets has announced the ... (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, ... Global Forecast to 2021" report to their offering. ... pharmaceutical excipients market is projected to reach USD 8.1 ... the forecast period 2016 to 2021. ...
Breaking Medicine Technology: